Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective

Cites (209)

Items 201–208 of 208

1. Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa
   Astrid‐Helene Ravn Jørgensen, Yiqiu Yao, Simon Francis Thomsen · 2018 · Case Reports in Dermatological Medicine
2. Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans
   Maria Carolina Amezcua Vesely, Constanza Rodríguez, Adriana Gruppi, Eva V. Acosta Rodríguez · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
3. A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases
   Michael A. Lyman, Vincent Lieuw, Robyn Richardson, A. Timmer, Christine Stewart, S. Granger, Richard H Woods, M. Silacci, D. Grabulovski, R. Newman · 2018 · Journal of Biological Chemistry
4. Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets
   Tevi Wain, Bonita Choy, Andrew C. Satchell, Jane A. Woods, John W. Frew · 2018 · JAAD Case Reports
5. Exposure–response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis
   Amit Khatri, Ben Klünder, Paul Michael J Peloso, Mohamed I. A. Othman · 2018 · Lara D. Veeken
6. The Evolution of the Immune System
   Davide Malagoli · 2016 · Elsevier eBooks
7. CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study
   Philip J. Mease, Sławomir Jeka, Juan José Jaller, Tasanee Kitumnuaypong, Worawit Louthrenoo, Herman F. Mann, Galina Matsievskaia, Enrique Roberto Soriano, Bin Jia, Caihong Wang et al. · 2017 · The Journal of Rheumatology
8. Untitled work
   Pope · 2001 · 10.1002/1529-0131(200106)44:6